These events may occur in the field of translational medicine in 2018

[market analysis of chinapharma.com] Michael Gladstone looks forward to the major events in the field of translational medicine this year, including the echo 301 trial to be published in the first half of this year, which will have an important impact on the Ido hypothesis and the development of the whole PD-1 combination therapy; as the halo of Ido fades, other early mechanisms begin to be paid attention to; Car-t enters the mainstream irresistibly, especially the big pharmaceutical companies with blood tumor product line almost have a place in car-t News events today Michael Gladstone of lifescivc looks forward to major events in the field of translational medicine this year Echo301 will be a big unsuccessful adult trial this year, but he estimates that the work in the field of IDO is just the beginning, no matter whether it is successful or not, because the details of indications, population, dosage, drug selectivity and so on will not be fully clarified because of one trial result The cytokine drugs with high activity and narrow window, such as CD122, CD25 specific IL2 derivatives, IL10 and so on, will also have important progress Car-t drugs into the mainstream, anti-inflammatory drugs to treat cardiovascular disease, gene therapy in full bloom are the other major events in his eyes The echo 301 trial to be published in the first half of this year will have an important impact on the development of IDO hypothesis and the whole PD-1 combination therapy I agree that if echo301 succeeds, many enterprises will continue to optimize indicators such as indications, dosage and drug selectivity to find their own me better, but if this trial fails, these problems will basically become theoretical problems, and the number of people interested will be greatly reduced Other mechanisms can also ask these questions, investors will not be very interested in a failed drug autopsy report, Ido will become a secondary target The two early immunotherapies, IL-2 and CTLA-4 antibody, have narrow therapeutic window and have not caused much influence, so they are not all successful After PD-1 was born, people's expectation of immunotherapy increased by an order of magnitude, which is the ideal environment for false positive Referring to the historical experience of platinum drugs and targeted therapy, the possibility of IDO failure is not small With the fading of the halo of IDO, other early mechanisms have attracted more and more attention Nktr214, a selective agonist of CD122 (a chain of IL2 receptor), was introduced After clinical results were released at SITC annual meeting last year, nktr has gained 7 billion US dollars because of this product And some companies are developing drugs that selectively activate another chain of IL-2 receptor CD25 as autoimmune diseases drugs Last year, Lilly purchased a low-dose IL-2 preparation for autoimmune diseases As an immunosuppressive factor, IL10 has been shown inexplicably to be an early anti-tumor therapeutic agent, which will also attract some trackers Last year's Cantos test of Novartis' IL-1 antibody, canakinumab, not only proved that inhibition of the immune system can improve the prognosis of cardiovascular disease, but also confirmed the biological marker of hsCRP Other mechanism drugs such as NLRP3 now have a simple and reliable optimization goal, and will rush to the important cardiovascular market Car-t enters the mainstream irresistibly, especially the big pharmaceutical companies with blood tumor product line almost have a place in car-t There is a rumor today that Xinji, the boss of multiple myeloma, may spend 10-12 billion to buy Juno, although Xinji said publicly last year that it would not Juno's recent performance is not very good, besides the safety event efficacy as a latecomer is not ideal, but the new base needs this treatment plate Gene therapy does have a trend of full bloom now In addition to the progress of blindness, hemophilia and other fields, a DMD patient received gene therapy for the second time today Gene editing therapy is also expected to start producing human data this year As the author said, these events may not be the major catalytic events of this year, but they are all events that start to blossom and bear fruit after long-term social input It usually takes decades from conjecture to technology discovery to transformation into clinical therapy These therapies are really technologies accumulated for a long time, which are left in waves It is exciting to concentrate and mature in a short time In the eyes of an investor, these are the main hot spots worthy of consideration by R & D personnel In addition to Ido being a small molecule drug, other drugs are all biotechnology, which shows that the research and development of small molecule drugs need disruptive innovation In addition to IL1, other technologies are aimed at specific diseases, and drug development for common diseases obviously needs new ideas Original title: VC forecast major events in 2018 pharmaceutical industry author: Lu renc